James Hallifax, The Psychedelic Investor, shares the two things he looks at when evaluating a medicinal psychedelic company.
Similar Posts
Interview With Carlos Tanner
In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.
The Spotlight Roundup- This Psychedelic VR Startup Raises Over $11 Million
August 4, 2021- This week’s Psychedelic Business News top stories…
Why Psychedelic Stocks are NOT Cannabis 2.0 (Huge MindMed Stock Opportunity)
In today’s episode, we will be discussing why Psychedelic Stocks, like MindMed (MMED / MMEDF) and Compass Pathways (CMPS) are not Cannabis 2.0, and why psychedelic stock prices will not follow the same path. For those who remember, Pot Stocks skyrocketed on the news of legalization, and then quickly tumbled back down to earth.
Some have dismissed companies like MindMed (MMED/MMEDF) and Compass Pathways (CMPS) as just the cannabis hype 2.0.
This, however, could not be further from the truth.
To be clear stocks like, MindMed Stock ( MMED : NEO market) and (MMEDF : OTC market), and Compass Pathways stock, ticker symbol CMPS are nothing like cannabis stocks.
To explain why, we are going to discuss an article entitled , “Why The Psychedelics Market is not Cannabis 2.0”, written by Jeff Siegel.
Psychedelic stocks are comparables to biotech companies these days. The prospect of promising research is pushing valuations upwards There are plenty of psychedelic stocks have experienced triple-digit returns in the last twelve months:
MindMed Stock MMED/MMEDF): 864%
Numinuss Wellness (NUMI): 555%
Revive Therapeutics (RVV): 166%
Compass Pathways (CMPS): 88%
The psychedelic industry is only just commencing. Other psychedelic stocks will soon penetrate the market and early investors can benefits from the shroom boom with 10X to 20X gains.
#psychedelicstocks #shroomstocks #mindmedstock
https://www.benzinga.com/markets/cannabis/21/01/19008810/why-the-psychedelics-market-is-not-cannabis-2-0
Remember to Like, Subscribe, and SMAH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
Interview with Victoria and Joël, of Tandava Retreats
Swati sits down with leaders from Kaivalya Kollectiv, “a multifaceted company focusing on psychedelic wellness, education”, and more. She speaks with Victoria Wueshner, a 5-MeO-DMT Facilitator and the Founder of FIVE, and Joël Brierre, CEO of Kaivalya Kollectiv.
BREAKING NEWS: Psychedelics ETF, PSIL, to launch THIS WEEK
BREAKING NEWS: Advisor Share Psychedelic Medicines ETF, PSIL, is going live THIS WEEK!!!!
Investing in ETFs can be a good way for retail investors to cash in on the shroom boom. This actively managed ETF will be managed by professionals who will do research on which companies have scientific and financial advantages.
PSIL will be on the NYSE, and will most likely feature companies such as MindMed (MNMD), Compass Pathways (CMPS), atai Life Sciences (atai), Numinus (NUMI) and more.
It will be a pure play psychedelics medicines ETF, and will not include marijuana companies (YAY). This means companies working with LSD, MDMA, Psilocybin and more. Primarily it is focused on improving mental health, so tackling problems like depression, PTSD addiction and more
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifa…
https://benzinga.grsm.io/thepsychedel…
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#AdvisorShares #PSIL #ThePsychedelicInvestor
Famous Biochemist, Shawn Wells, Tells All About Psychedelics
The World’s leading nutritional biochemist and thought leader on human optimization, Shawn Wells, tells all about psychedelics.